The credit facility de-risks the balance sheet ahead of pivotal Phase 2 data for RP-A501 (mid-2028). The staged structure aligns capital access with clinical milestones, reducing equity dilution risk. Monitor Tranche 2 Milestone achievement (Positive Data from Registrational Study) as the catalyst for an additional $30M draw and potential maturity extension. The positive early safety data from Cohort 4 supports the recalibrated dose strategy and de-risks the pivotal readout.
Price Chart
Executive Summary
Rocket Pharmaceuticals entered into a $150M senior secured credit facility with Hercules Capital, receiving an initial $35M tranche at closing. The facility provides staged funding tied to clinical milestones for RP-A501 (Danon disease), with interest-only payments through April 2029 and a 48-month maturity. Concurrently, the company issued warrants to purchase up to 1,755,853 shares at $2.99, with 409,699 shares immediately exercisable. The company also released positive Phase 2 clinical data showing no TMA or complement-mediated toxicities in the first 3 Cohort 4 patients at the recalibrated dose, with a clear path to BLA submission for accelerated approval targeted for late 2028.
Key Financial Metrics
Key Facts
- Up to $150M senior secured credit facility from Hercules Capital; initial $35M Tranche 1-A funded at closing on September 30, 2026
- Additional tranches: $20M Tranche 1-B (available through June 2027), $15M Tranche 1-C (through Sep 2027), $30M Tranche 2 (upon Tranche 2 Milestone), $50M Tranche 3 (discretionary)
- Interest rate: Prime Rate (floor 6.75%) + 2.40%; interest-only through April 2029, extendable to Oct 2030 upon milestones
- Maturity: October 1, 2030, extendable to October 1, 2031 upon Tranche 2 Milestone achievement
- Warrants issued to Lenders to purchase up to 1,755,853 shares at $2.99 exercise price; 409,699 shares immediately exercisable post-Tranche 1-A
- Minimum cash covenant: Qualified Cash >= 35%-75% of outstanding Term Loans (depending on milestone achievement); not tested if market cap > $600M
- Cash runway extended into Q3 2028 with initial $35M; additional draws could extend into 2029
- Phase 2 Cohort 4 (recalibrated dose 3.8x10^13 GC/kg) shows no TMA, capillary leak, or complement-mediated toxicities in first 3 patients through 3 months
- Pivotal Phase 2 study of RP-A501 targeting 12 patients at recalibrated dose; dosing completion expected mid-2027, top-line data mid-2028, BLA filing late 2028
- As of June 30, 2026, Rocket had $283.7M in cash, cash equivalents and investments
Financial Impact
Up to $150M in senior secured debt financing; initial $35M drawn at closing extends cash runway into Q3 2028. Additional draws contingent on clinical milestones could extend runway into 2029. Warrants represent potential dilution of up to 1,755,853 shares at $2.99, with 409,699 shares immediately exercisable.
Risk Factors
- Failure to achieve Tranche 2 Milestone or Approval Milestone would limit access to $30M Tranche 2 and $50M discretionary Tranche 3
- Minimum cash covenant (35%-75% of outstanding debt) could restrict operational flexibility if cash burn accelerates
- Warrant dilution of up to 1,755,853 shares (409,699 immediately exercisable) at $2.99 per share
- Clinical risk: RP-A501 pivotal study failure or safety issues could trigger covenant defaults and accelerate debt repayment
- Interest rate exposure: floating rate (Prime + 2.40%) with Prime floor at 6.75%
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-038818 |
| Document: ef20083350_ex10-2.htm | 0001140361-26-038818 |
| Document: ef20083350_ex99-2.htm | 0001140361-26-038818 |
| Document: ef20083350_8k.htm | 0001140361-26-038818 |
| Document: ef20083350_ex99-1.htm | 0001140361-26-038818 |
| Document: 0001140361-26-038818-index-headers.html | 0001140361-26-038818 |
| Document: 0001140361-26-038818-index.html | 0001140361-26-038818 |
| Document: 0001140361-26-038818.txt | 0001140361-26-038818 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $2.54 | awaiting T+20 | — | $2.28 (−10.06%) |
Sep 15, 2026 5w ago | 8-K | $3.41 $2.30 | ▼ −32.55% | ▼ −35.27% | $2.28 (−33.14%) |
Aug 20, 2026 9w ago | Insider Cluster | $3.51 $3.27 | ▼ −6.84% | ▼ −7.85% | $2.28 (−35.04%) |
Aug 17, 2026 10w ago | Insider Cluster | $3.34 $3.49 | ▲ +4.49% | ▲ +5.48% | $2.28 (−31.74%) |
Aug 13, 2026 10w ago | Insider Cluster | $3.47 $3.43 | ▼ −1.15% | ▲ +0.84% | $2.28 (−34.29%) |
Aug 10, 2026 11w ago | 8-K | $3.50 $3.63 | ▲ +3.71% | ▲ +4.77% | $2.28 (−34.86%) |
Aug 3, 2026 12w ago | 8-K | $3.41 $3.72 | ▲ +9.09% | ▲ +7.85% | $2.28 (−33.14%) |
Jun 30, 2026 16w ago | 8-K | $3.52 $3.14 | ▼ −10.80% | ▼ −8.61% | $2.28 (−35.23%) |
Jun 12, 2026 19w ago | 8-K | $2.75 $3.91 | ▲ +42.18% | ▲ +40.40% | $2.28 (−17.09%) |
May 26, 2026 21w ago | Insider Cluster | $2.99 $3.24 | ▲ +8.36% | ▲ +10.26% | $2.28 (−23.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers